Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: Implications for regimen choice

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Heysell, Scott K ^a   Ahmed, Shahriar ^b   Ferdous, Sara Sabrina ^b   Khan, Md Siddiqur Rahman ^b   Rahman, S M Mazidur ^b   Gratz, Jean ^a   Rahman, Md Toufiq ^b   Mahmud, Asif Mujtaba ^c   Houpt, Eric R ^a   Banu, Sayera ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^c National Institute of Diseases of Chest and Hospital   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BANGLADESH; CLINICAL FEATURE; CONTROLLED STUDY; DRUG CHOICE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84923323272     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116795     Document Type: Article

References (39)

1. Shenoi S, Heysell SK, Moll AP, Friedland G (2009) Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis 22: 11-17 doi: 10.1097/QCO.0b013e3283210020 PMID: 19532076
2. Gandhi NR, Nunn P, Dheda P, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375: 1830-43 doi: 10.1016/S0140-6736(10)60410-2 PMID: 20488523
3. World Health Organization (2013) Global Tuberculosis Report 2013. Geneva: World Health Organization. doi: 10.1002/cpp.1875 PMID: 25625597
4. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377:1495-1505. doi: 10.1016/S0140-6736(11)60438-8 PMID: 21507477
5. Barnard M, Albert H, Coetzee G, O'Brian R, Bosman ME (2008) Rapid molecular screening for multi-drug- resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 177(7): 787-792. doi: 10.1164/rccm.200709-1436OC PMID: 18202343
6. World Health Organization (2011) Guideline for the programmatic management of drug resistant tuberculosis. Emergency update. Geneva: WHO/HTM/TB.
7. van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, et al. (2010) Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182:684-692. doi: 10.1164/rccm.201001-0077OC PMID: 20442432
8. Hall L, Jude KP, Clark SL, Dionne K, Merson R, et al. (2012) Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents. J Clin Microbiol 50:3732-3734. doi: 10.1128/JCM.02048-12 PMID: 22895034
9. Banu S, Rahman SMM, Khan MSR, Ferdous S, Ahmed S, et al. (2014) Discordance across several drug susceptibility methods for drug-resistant tuberculosis in a single laboratory. J Clin Micro 52(1): 156-63. doi: 10.1128/JCM.02378-13 PMID: 24172155
10. Lee J, Armstrong DT, Ssengooba W, Park J, Yu Y, et al. (2014) Sensititre MYCOTB MIC Plate for Testing Mycobacterium tuberculosis Susceptibility to First- and Second-Line Drugs. J Clin Micro 58(1):11.
11. Abuali MM, Katariwala R, LaBombardi VJ (2012) A comparison of the Sensititre MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 31:835-839 doi: 10.1007/s10096-011-1382-z PMID: 21866324
12. Mpagama S, Houpt ER, Stroup S, Kumburu H, Gratz J, et al. (2013) Application of quantitative secondline drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. BMC Infect Dis 13: 432. doi: 10.1186/1471-2334-13-432 PMID: 24034230
13. Rowlinson MC (2013) MICs in TB susceptibility testing: Florida bureau of public health laboratories. San Diego: Eighth National Conference on Laboratory Aspects of Tuberculosis, Association of Public Health Laboratories.
14. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, et al. (1969) Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41:21-43. PMID: 5309084
15. World Health Organization (2007) Use of liquid TB culture and drug susceptibility testing (DST) in low and medium income settings. Summary report of the Expert Group Meeting on the Use of Liquid Culture Media. Geneva: World Health Organization.
16. Clinical Laboratory Standards Institute (2003) Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes: approved standard. CLSI document M24-A (ISBN 1-56238-550-3). Clinical Laboratory Standards Institute, Wayne, PA
17. Heifets L (1998) Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis 137:1217-1222.
18. Iseman M (2000) Drug-resistant tuberculosis. In: A Clinician's guide to tuberculosis. Philadelphia: Lippincott Williams and Wilkins. pp 323-350. doi: 10.4103/0974-1208.147490 PMID: 25625472
19. Somoskovi1 A, Deggim V, Ciardo D, Bloemberg GV (2013) Inconsistent Results with the Xpert-MTB/ Rif Assay in Detection of Mycobacterium tuberculosis with an rpoB Mutation Associated with Low Level of Rifampin Resistance: Diagnostic Implications. J Clin Micro 51(9) 3127-3129. doi: 10.1128/JCM.01377-13 PMID: 23850949
20. Williamson DA, Roberts SA, Bower JE, Vaughan R, Newton S, et al. (2012) Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 16:216-220. doi: 10.5588/ijtld.11.0178 PMID: 22137551
21. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, et al. (2009) Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 47:3501-3506. doi: 10.1128/JCM.01209-09 PMID: 19759221
22. Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, et al. (2014) Profiling of rpoB Mutations and MICs to Rifampicin and Rifabutin in Mycobacterium tuberculosis. J Clin Microbiol 52:2157-2162. doi: 10.1128/JCM.00691-14 PMID: 24740074
23. Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER (2013) Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, U.S.A. Tuberc Res Treat epub 10.1155/2013/129723.
24. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, et al. (2011) Why Do We Use 600 mg of Rifampicin in TuberculosisTreatment? Clin Infect Dis 52 (9): e194-e199 doi: 10.1093/cid/cir184 PMID: 21467012
25. th Conference on Retroviruses and Opportunistic Infections; March 2013; Atlanta.
26. Jo KW, Ji W, Hong Y, Lee SD, Kim WS, et al. (2013) The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. Respir Med 107:292-7. doi: 10.1016/j.rmed.2012.10.021 PMID:23199704
27. Yang B, Koga H, Ohno H, Ogawa K, Fukuda M, et al. (1998) Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 42:621-8. PMID: 9848446
28. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, et al. (1998) Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:1853-7. PMID: 9661035
29. Caminero JA, Sotgiu G, Zumla A, Migliori GB (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10: 621-29 doi: 10.1016/S1473-3099(10)70139-0 PMID: 20797644
30. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A (2014) Costs of tuberculosis disease in the EU-a systematic analysis and cost calculation. Euro Respir Journal 43(2): 554-565. doi: 10.1183/09031936.00079413 PMID: 23949960
31. Mpagama S, Ndusilo N, Stroup S, Gratz J, Kumburu H, et al. (2014) Plasma drug activity in patients treated for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 58(2):782. doi: 10.1128/AAC.01549-13 PMID: 24247125
32. Pasipanodya J, McIlleron H, Burger A, Walsh PA, Smith P, et al. (2013) Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1564-73.
33. Akkerman OW, van Altena R, Klinkenberg T, Brouwers AH, Bongaerts AHH, et al. (2013) Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Respir J 42:1750-2. doi: 10.1183/09031936.00047413 PMID: 24293422
34. Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, et al. (2012) Population Pharmacokinetics and Pharmacodynamics of Ofloxacin in South African Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother 56(7):3857-3863. doi: 10.1128/AAC.00048-12 PMID: 22564839
35. Peloquin CA, Hadad DJ, Pereira Dutra Molino L, Palaci M, Boom WH, et al. (2008) Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 52: 852-57. PMID: 18070980
36. Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, et al. (2014) Improving outcomes for multidrug-resistant tuberculosis: Aggressive regimens prevent treatment failure and death. Clin Infect Dis May 7. [Epub ahead of print]
37. Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, et al. (2012) Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res 22: 735-745 doi: 10.1101/gr.128678.111 PMID: 22294518
38. Zaunbrecher MA, David Sikes RD, Metchock B, Shinnick TM, Posey JE (2009) Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Nat Acad Science 106 (47).
39. Pfyffer GE, Bonato DA, Ebrahimzadeh A, Gross W, Hotaling J, et al. (1999) Multicenter Laboratory Validation of Susceptibility Testing of Mycobacterium tuberculosis against Classical Second-Line and Newer Antimicrobial Drugs by Using the Radiometric BACTEC 460 Technique and the Proportion Method with Solid Media. J Clin Microbiol 37(10): 3179-86. PMID: 10488174